Duchenne News Tags: Sarepta

September 29, 2022
Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy.
September 13, 2022
On September 13, 2022, Sarepta Therapeutics shared an update announcing that their EMBARK (SRP-9001-301) study is fully enrolled.
September 7, 2022
On Sept. 7, 2022, Sarepta Therapeutics announced the recipients for its Route 79, Duchenne Scholarship Program for the 2022-2023 academic year.
September 6, 2022
On Sept. 6, 2022, Sarepta Therapeutics announced that the Food and Drug Administration lifted its clinical hold on SRP-5051 for the treatment of Duchenne muscular dystrophy.
July 6, 2022
On July 6, 2022, Sarepta Therapeutics shared new functional data across multiple studies from the clinical development program for investigational gene therapy SRP-9001.
June 23, 2022
On June 23, 2022, Sarepta shared news regarding the MOMENTUM study.
June 9, 2022
On June 9, 2022, Sarepta provided a community update on their actively recruiting clinical trial programs for Duchenne muscular dystrophy.